| Date Filed | Type | Description |
| 02/17/2015 |
SC 13G/A
| RA CAPITAL MANAGEMENT, LLC reports a 0% stake in Furiex Pharmaceuticals, Inc. |
| 02/17/2015 |
SC 13G/A
| Consonance Capital Management LP reports a 0% stake in Furiex Pharmaceutical, Inc |
| 02/06/2015 |
SC 13G/A
| THOMPSON SIEGEL & WALMSLEY LLC reports a 0% stake in FURIEX PHARMACEUTICALS INC. |
| 07/08/2014 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/07/2014 |
4
| Forest Laboratories, LLC (10% Owner) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Bought 11,169,066 shares
@ $95, valued at
$1061.1M
Bought 11,169,066 shares
@ $95, valued at
$1061.1M
|
|
| 07/07/2014 |
SC 13D
| Magnetar Financial LLC reports a 10% stake in Furiex Pharmaceuticals, Inc. |
| 07/07/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/07/2014 |
4
| McIntyre Gail Frances (Senior Vice President-Research) has filed a Form 4 on Furiex Pharmaceuticals, Inc. |
| 07/07/2014 |
4
| COVINGTON PAUL S (Senior VP-Clinical Operations) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 22,523 shares
@ $0
Disposed/sold 26,000 options to buy
@ $15, valued at
$390k
Disposed/sold 37,944 options to buy
@ $13.16, valued at
$499.3k
|
|
| 07/07/2014 |
4
| DIXON WENDY L (Director) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 7,160 shares
@ $0
Disposed/sold 17,570 options to buy
@ $9.11, valued at
$160.1k
Disposed/sold 8,675 options to buy
@ $13.94, valued at
$120.9k
Disposed/sold 8,825 options to buy
@ $13.45, valued at
$118.7k
Disposed/sold 17,500 options to buy
@ $18.22, valued at
$318.9k
|
|
| 07/07/2014 |
4
| Patel Sailash (CFO) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 26,444 shares
@ $0
Disposed/sold 26,360 options to buy
@ $9.11, valued at
$240.1k
Disposed/sold 20,000 options to buy
@ $15, valued at
$300k
Disposed/sold 29,644 options to buy
@ $13.16, valued at
$390.1k
Disposed/sold 8,294 options to buy
@ $17.8, valued at
$147.6k
|
|
| 07/07/2014 |
4
| CORR PETER B (Director) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 8,447 shares
@ $0
Disposed/sold 5,470 options to buy
@ $9.11, valued at
$49.8k
Disposed/sold 8,675 options to buy
@ $13.94, valued at
$120.9k
Disposed/sold 8,825 options to buy
@ $13.45, valued at
$118.7k
Disposed/sold 17,500 options to buy
@ $18.22, valued at
$318.9k
|
|
| 07/07/2014 |
4
| Almenoff June Sherie (President) has filed a Form 4 on Furiex Pharmaceuticals, Inc. |
| 07/07/2014 |
4
| Kaldor Stephen W (Director) has filed a Form 4 on Furiex Pharmaceuticals, Inc. |
| 07/07/2014 |
4
| DAVIS STEPHEN (Director) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 9,308 shares
@ $0 |
|
| 07/03/2014 |
8-K
| Form 8-K - Current report |
| 07/03/2014 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/01/2014 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/26/2014 |
4
| Patel Sailash (CFO) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 32,928 shares
@ $104, valued at
$3.4M
Exercised 32,928 options to buy
@ $9.11, valued at
$300k
|
|
| 06/26/2014 |
4
| COVINGTON PAUL S (Senior VP-Clinical Operations) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 10,368 shares
@ $104.12, valued at
$1.1M
Exercised 10,368 options to buy
@ $17.8, valued at
$184.6k
|
|
| 06/23/2014 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/20/2014 |
4
| COVINGTON PAUL S (Senior VP-Clinical Operations) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 45,691 shares
@ $104.11, valued at
$4.8M
Exercised 45,691 options to buy
@ $9.11, valued at
$416.2k
|
|
| 06/18/2014 |
4
| McIntyre Gail Frances (Senior Vice President-Research) has filed a Form 4 on Furiex Pharmaceuticals, Inc. |
| 06/17/2014 |
4
| COVINGTON PAUL S (Senior VP-Clinical Operations) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 3,228 shares
@ $104.25, valued at
$336.5k
|
|
| 06/16/2014 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/12/2014 |
4
| COVINGTON PAUL S (Senior VP-Clinical Operations) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 2,872 shares
@ $104.63, valued at
$300.5k
|
|
| 06/12/2014 |
4
| McIntyre Gail Frances (Senior Vice President-Research) has filed a Form 4 on Furiex Pharmaceuticals, Inc. |
| 06/12/2014 |
4
| Patel Sailash (CFO) has filed a Form 4 on Furiex Pharmaceuticals, Inc.|
Txns:
| Sold 1,504 shares
@ $104.68, valued at
$157.4k
|
|
| 06/04/2014 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 05/28/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/09/2014 |
10-Q
| Quarterly Report for the period ended March 31, 2014 |
| 05/09/2014 |
SC 13G
| MORGAN STANLEY reports a 5.3% stake in FURIEX PHARMACEUTICALS, INC. |
| 05/07/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
|